Biorem Inc (BRM) AI Stock Analysis

• Market Cap: C$30.66M
• Dividend Yield: N/A
• Average Volume (3M): 32.44K
• Price to Earnings (P/E): 9.6
• Beta (1Y): 0.38
• Revenue Growth: 24.01%
• EPS Growth: -11.48%
• Country: CA
• Employees: 57
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Pollution & Treatment Controls
• EPS (TTM): 0.04
• Shares Outstanding: 16,137,438
• 10 Day Avg. Volume: 30,537
• 30 Day Avg. Volume: 32,440
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 74 Outperform
• Price Target: C$2.50 ▲(24.38% Upside)

Biorem Inc's strong financial performance is the most significant factor driving the stock score, reflecting robust growth and a stable financial foundation. The technical analysis suggests a neutral market sentiment, while the valuation indicates the stock is reasonably priced. The absence of earnings call and corporate events data did not impact the score.

Biorem Inc Business Overview & Revenue Model

Company Description

Biorem Inc (BRM) is a leader in the environmental biotechnology sector, specializing in the development and implementation of innovative solutions for the treatment of wastewater, air emissions, and contaminated soil. The company utilizes advanced bioremediation technologies to help clients across various industries, including municipal, industrial, and agricultural sectors, to manage and mitigate environmental pollutants while promoting sustainability. Core products and services include biofilters, bioreactors, and consulting services that enhance the efficiency and effectiveness of environmental remediation efforts.

How the Company Makes Money

Biorem Inc generates revenue primarily through the sale of its proprietary bioremediation technologies and systems, which include biofilters and bioreactors. The company also earns money through consulting services that help clients design and implement effective environmental management strategies. Key revenue streams include direct product sales, long-term service contracts, and performance-based agreements where Biorem is compensated based on the effectiveness of its solutions. Significant partnerships with governmental agencies and private sector companies also contribute to its earnings, as these collaborations often lead to larger projects and increased market visibility.

Biorem Inc Financial Statement Overview

Summary

Biorem Inc has shown remarkable financial improvement with strong revenue growth, improved profit margins, and robust cash flow metrics. The company's low debt-to-equity ratio and high return on equity further highlight its solid financial position.

Income Statement

Biorem Inc has demonstrated strong revenue growth with a significant increase of 48.67% in 2024 compared to the previous year. The gross profit margin stands at 26.87%, reflecting efficient cost management. The net profit margin also improved to 8.13%, indicating enhanced profitability. Both EBIT and EBITDA margins show positive trends, at 11.61% and 12.87% respectively, highlighting operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is 0.33, indicating a healthy leverage position. Return on equity has improved to 28.65%, showcasing effective utilization of shareholder funds. The equity ratio is 37.26%, which suggests a stable capital structure with a good portion of assets financed by shareholders' equity.

Cash Flow

Biorem Inc's free cash flow growth rate is robust, reflecting a turnaround from negative to positive free cash flow. The operating cash flow to net income ratio of 1.21 indicates strong cash generation relative to net income, while the free cash flow to net income ratio of 1.09 further confirms solid cash flow health.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.36M	37.42M	25.17M	28.86M	24.48M	24.38M
Gross Profit	10.28M	10.06M	7.02M	8.76M	6.24M	7.02M
EBITDA	5.03M	4.82M	3.45M	2.99M	2.68M	3.07M
Net Income	3.14M	3.04M	2.18M	1.61M	1.30M	2.09M
Balance Sheet
Total Assets	27.10M	28.51M	24.08M	20.73M	19.17M	21.95M
Cash, Cash Equivalents and Short-Term Investments	7.66M	5.21M	2.29M	3.78M	4.47M	8.87M
Total Debt	3.14M	3.56M	4.19M	4.75M	5.67M	828.17K
Total Liabilities	16.16M	17.89M	17.36M	16.21M	17.20M	8.43M
Stockholders Equity	10.94M	10.63M	6.72M	4.52M	1.96M	13.52M
Cash Flow
Free Cash Flow	4.42M	3.31M	-62.84K	1.24M	3.71M	2.99M
Operating Cash Flow	4.76M	3.69M	490.03K	1.44M	3.78M	3.34M
Investing Cash Flow	-345.11K	-372.00K	-552.87K	-203.29K	-75.98K	-342.40K
Financing Cash Flow	-567.52K	-572.04K	-1.33M	-951.80K	-7.56M	-199.74K

Biorem Inc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.01
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BRM, the sentiment is Neutral. The current price of 2.01 is above the 20-day moving average (MA) of 1.98, below the 50-day MA of 2.02, and below the 200-day MA of 2.21, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.12 is Neutral, neither overbought nor oversold. The STOCH value of 72.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:BRM.

Biorem Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BRM	―	C$30.66M	9.59	33.38%	―	24.01%	-11.48%
TMG	―	C$21.64M	―	-1.51%	―	-3.45%	-104.92%
Sector *	―	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
GRN	―	C$40.81M	288.89	0.73%	―	-31.63%	―
WATR	―	C$6.16M	―	-1238.40%	―	-72.45%	-987.50%
SHRC	―	C$13.03M	―	-2546.33%	―	25.83%	-30.00%
QST	―	C$15.97M	―	-4.12%	―	75.22%	83.79%

Biorem Inc Corporate Events

Biorem Inc. Reports Strong Q2 2025 Results with Increased Revenue and Order Backlog

Biorem Inc. reported a significant increase in revenue for the second quarter of 2025, reaching $9.4 million, which marks a 29% increase compared to the same period in 2024. This growth is attributed to an increase in orders and a substantial order backlog, which is expected to support strong revenues and earnings in the latter half of the year. Despite logistical challenges earlier in the year, the company successfully accelerated shipments to international customers, maintaining its delivery forecasts. The company’s focus on offering integrated service solutions is anticipated to drive growth in both domestic and international markets over the next several quarters.

The most recent analyst rating on (TSE:BRM) stock is a Buy with a C$2.50 price target. To see the full list of analyst forecasts on Biorem Inc stock, see the TSE:BRM Stock Forecast page.